VERACYTE, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
VERACYTE, INC. (VCYT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $14.90 per share for the 12-month period ending 2023-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-02-26
- VERACYTE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2016-03-31 was $3.36, a 37.43% decline year-over-year.
- VERACYTE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2015-03-31 was $5.37, a 47.71% decline year-over-year.
- VERACYTE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2014-03-31 was $10.27, a 278.97% increase year-over-year.
- VERACYTE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2013-03-31 was $2.71.
- VERACYTE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $14.90, a 1.98% increase from fiscal 2022.
- VERACYTE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $14.61, a 37.70% decline from fiscal 2021.
- VERACYTE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $23.45, a 80.80% increase from fiscal 2020.
- VERACYTE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2020 was $12.97, a 17.16% increase from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2023-12-31 | $14.90 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $14.61 10-K · filed 2025-02-28 | |||
| 2021-12-31 | $23.45 10-K · filed 2024-02-29 | |||
| 2020-12-31 | $12.97 10-K · filed 2023-03-01 | |||
| 2019-12-31 | $11.07 10-K · filed 2022-02-28 | |||
| 2018-12-31 | $3.62 10-K · filed 2021-02-22 | |||
| 2017-12-31 | $4.49 10-K · filed 2020-02-25 | |||
| 2016-12-31 | $3.35 10-K · filed 2019-02-25 | |||
| 2016-09-30 | $3.29 10-Q · filed 2016-11-03 | |||
| 2016-06-30 | $3.30 10-Q · filed 2016-08-03 | |||
| 2016-03-31 | $3.36 10-Q · filed 2016-05-05 | |||
| 2015-12-31 | $5.12 10-K · filed 2018-02-27 | |||
| 2015-09-30 | $5.23 10-Q · filed 2016-11-03 | |||
| 2015-06-30 | $5.36 10-Q · filed 2016-08-03 | |||
| 2015-03-31 | $5.37 10-Q · filed 2016-05-05 | |||
| 2014-12-31 | $9.08 10-K · filed 2017-03-01 | |||
| 2014-09-30 | $9.74 10-Q · filed 2015-11-05 | |||
| 2014-06-30 | $9.97 10-Q · filed 2015-08-13 | |||
| 2014-03-31 | $10.27 10-Q · filed 2015-05-15 | |||
| 2013-12-31 | $4.19 10-K · filed 2016-03-14 | |||
| 2013-09-30 | $3.73 10-Q · filed 2014-11-13 | |||
| 2013-06-30 | $3.18 10-Q · filed 2014-08-14 | |||
| 2013-03-31 | $2.71 10-Q · filed 2014-05-09 | |||
| 2012-12-31 | $1.95 10-K · filed 2015-03-25 | |||
| 2012-09-30 | $1.88 10-Q · filed 2013-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| BIODESIX INC (BDSX) | United States | $0.312B |